CFI-400945 is under clinical development by Treadwell Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CFI-400945’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CFI-400945 overview
CFI-400945 is under development for the treatment of chronic myelomonocytic leukemia, relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome, advanced solid tumors including advanced and metastatic triple negative breast cancer, HER2 negative breast cancer, metastatic castration-resistant prostate cancer. It is a small molecule formulated as tablet and administered through oral route. It targets polo-like kinase 4 (PLK4). It was also under development for ovarian cancer, pancreatic cancer and lung cancer.
Treadwell Therapeutics overview
Treadwell Therapeutics is a clinical-stage biotechnology company that develops novel therapeutics for highly aggressive cancers. The company’s pipeline products include small cell therapeutic products, biologic therapy and T-cell receptor (TCR) based cell therapy products. Its products are used in various therapeutic areas which include solid and liquid tumors, breast cancer, prostate cancer, myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), among others. Treadwell Therapeutics leverages deep mechanistic insights and internal discovery tools to uncover novel targets and translate those insights into clinical candidates. The company operates in the US, Canada and Hong Kong. Treadwell Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of CFI-400945’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
